Carregant...
A research agenda for moving early medical pregnancy termination over the counter
Given the overall safety profile and increasing availability of medical pregnancy termination drugs, we asked: would the mifepristone–misoprostol regimen for medical termination at ≤10 weeks of gestation meet US Food and Drug Administration regulatory criteria for over‐the‐counter (OTC) approval, an...
Guardat en:
| Publicat a: | BJOG |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5637897/ https://ncbi.nlm.nih.gov/pubmed/28317327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1471-0528.14646 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|